Hypertrophic cardiomyopathy and obstructive cardiomyopathy
Myokardia Inc. focuses on clinical research in hypertrophic cardiomyopathy, with particular attention to symptomatic obstructive hypertrophic cardiomyopathy and left ventricular outflow tract obstruction. The funded studies examine cardiac symptoms, physical limitation, and exercise capacity in affected adults.
- Symptomatic obstructive hypertrophic cardiomyopathy
- Left ventricular outflow tract obstruction
- Patient-reported health status
- Exercise capacity
Research activity also includes imaging-based evaluation of cardiac structure and myocardial thickness in relation to disease burden.
Non-obstructive hypertrophic cardiomyopathy
The sponsor supports trials in non-obstructive hypertrophic cardiomyopathy, addressing both clinical symptoms and longer-term cardiac outcomes. These studies include follow-up research in adults previously enrolled in earlier cardiomyopathy programs.
- Non-obstructive hypertrophic cardiomyopathy
- Long-term safety and tolerability
- Cardiac magnetic resonance imaging
- Cardiac mass and structure
Imaging assessments are used to examine changes in ventricular wall thickness and atrial size.
Genetic dilated cardiomyopathy
Myokardia Inc. also funds research in dilated cardiomyopathy linked to inherited variants, including MYH7 and TTN-associated disease. This area reflects interest in cardiomyopathy driven by specific genetic causes and reduced heart function.
- MYH7-related dilated cardiomyopathy
- TTN-related dilated cardiomyopathy
- Genetic heart failure
- Reduced cardiac function
Studies in this domain extend to other causal forms of primary dilated cardiomyopathy.
Cardiac myosin-targeted therapy
The sponsor’s research portfolio includes therapies directed at cardiac myosin in adults with cardiomyopathy. Clinical programs evaluate treatment effects across symptomatic disease, structural heart changes, and functional outcomes.
- Mavacamten
- MYK-224
- Danicamtiv
- Myocardial structure and function
These studies cover both obstructive and non-obstructive forms of cardiomyopathy, with attention to cardiac remodeling and disease-specific symptom control.
